Janus Henderson Group PLC Sells 129,687 Shares of Grifols, S.A. $GRFS

Janus Henderson Group PLC trimmed its position in Grifols, S.A. (NASDAQ:GRFS) by 3.8% during the first quarter, Holdings Channel reports. The firm owned 3,290,089 shares of the biotechnology company’s stock after selling 129,687 shares during the quarter. Janus Henderson Group PLC’s holdings in Grifols were worth $26,354,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of GRFS. Bank of Montreal Can grew its holdings in Grifols by 3,205.1% during the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after purchasing an additional 2,922,540 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Grifols by 383.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock valued at $27,894,000 after buying an additional 2,221,633 shares during the period. Norges Bank acquired a new stake in shares of Grifols in the fourth quarter valued at approximately $18,139,000. Brandes Investment Partners LP lifted its position in shares of Grifols by 6.3% in the fourth quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock valued at $289,422,000 after buying an additional 1,838,727 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of Grifols by 132.6% during the 4th quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock worth $22,764,000 after acquiring an additional 1,387,783 shares during the period.

Grifols Trading Down 0.1%

Shares of GRFS stock opened at $7.86 on Tuesday. Grifols, S.A. has a 12-month low of $6.96 and a 12-month high of $10.88. The company has a market capitalization of $5.35 billion, a PE ratio of 41.37, a price-to-earnings-growth ratio of 0.29 and a beta of 0.66. The firm has a 50 day moving average price of $7.51 and a two-hundred day moving average price of $8.16. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10.

Grifols Dividend Announcement

The company also recently declared a special dividend, which was paid on Thursday, July 9th. Investors of record on Thursday, July 2nd were paid a $0.0945 dividend. The ex-dividend date was Thursday, July 2nd. Grifols’s payout ratio is 121.05%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Weiss Ratings lowered Grifols from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, Wall Street Zen downgraded shares of Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $10.00.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.